Hint | Answer | % Correct |
---|---|---|
estogen inhibitor | tamoxifen | 80%
|
targets CD20 on B-cells | rituximab | 70%
|
targets HER-2 | Trastuzumab | 70%
|
inhibitor of the tyrosine kinase domain of Bcr-Abl (philadelphia chromosome) | imatinib | 60%
|
Beta tubulin assembly | vincristine | 40%
|
targets VEGR (required for angiogenesis) | bevacizumab | 30%
|
potent inhibitor of angiogenesis | thalidomide | 20%
|
intercalates DNA, inhibits topo 2, chelates iron | doxorubicin | 10%
|
topoisomerase II inhibitor (toxicity includes myelosuppression and 2nd leukemia) | etoposide | 10%
|
targets CTLA-4 | ipilmumab | 10%
|
targets PD-1 on T-cells | nivolumab | 10%
|
topoisomerase 1 inhibitor (DLT myelosuppression) | topotecan | 10%
|
androgen inhibitor | bicalutamide | 0%
|
binds DNA, resulting in single and double strand breaks following free radical formation and inhibition of DNA sythesis | bleomycin | 0%
|
inhibits proteosome | bortezumab | 0%
|
interacts with DNA at GC sites | dactinomycin | 0%
|
GnRH antagonist that causes testosterone suppression | degarelix | 0%
|
TKI that targets EGFR | erlotinib | 0%
|
topoisomerase I inhibitor (active metabolite SN38) | irinotecan | 0%
|
aromatase inhibitor | letrozole | 0%
|
agonist at pituitary GnRH receptors; leads to testosterone suppresion | leuprolide | 0%
|
intercalates DNA, inhibits topoisomerase 2, no free radical formation | mitoxantrone | 0%
|
beta tubulin- no disassembly | paclitaxel | 0%
|
inhibitor of CDK-4, CDK-6, and inactivates RB protein | palbociclib | 0%
|
TKI that inhibits VEGF and RAF | sorafenib | 0%
|
multiple receptor tryosine kinase inhibitor (inhibits VEGFR, PDGFR) | sunitinib | 0%
|
mTor inhibitor | temsirolimus | 0%
|
BRAF inhibitor | vemuramab | 0%
|
Copyright H Brothers Inc, 2008–2024
Contact Us | Go To Top | View Mobile Site